Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses various cancer prevention strategies, summarizing established successes like tamoxifen for breast cancer and mixed outcomes of preventive trials like finasteride for prostate cancer, and reports no new results.

This review discusses the roles of dihydrotestosterone in fetal development and adult diseases, reporting no new clinical results; the authors emphasize the potential of 5α-reductase inhibitors for treatment.

This article discusses developments in clinical urology featured in the Journal of Urology's October 1999 issue and presents no new clinical findings.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This review examines PAK4 signaling pathways in prostate cancer, Parkinson's disease, and melanogenesis, focusing on the potential role of the PAK4-CREB axis, without reporting new clinical results.

This article discusses historical aspects of gender development, particularly related to the discovery of finasteride, and reports no new clinical results.

This review discusses the roles of the transcription factor SOX9 in organ development and maintenance, providing insights into its regulation and diverse functions, but reports no new experimental results.

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.

A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.

This study found that finasteride treatment in men with benign prostate hyperplasia significantly altered steroid hormone profiles and may contribute to depressive symptoms by affecting neuroactive steroid levels.

This article reviews the role of hormones in human penis development and associated conditions due to hormonal imbalances, but reports no new findings, suggesting hormone replacement can manage some conditions.

This study found that SRD5A2 expression is absent in one third of benign adult prostates and is associated with hypermethylation, suggesting potential personalization of treatment for prostatic diseases based on methylation status.

This review discusses the etio-pathogenetic factors in benign prostatic hyperplasia and their role in the development of lower urinary tract symptoms but reports no new research findings.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This review discusses the American Society of Preventive Oncology's focus on cancer prevention and highlights the ongoing challenges and developments in screening, tobacco control, and the need for innovative risk-reduction strategies; it reports no new research findings.

This study reports that dutasteride, used alone or with tamsulosin, effectively reduces acute urine retention and surgery risk in men with benign prostatic hyperplasia, and may lower prostate cancer incidence, suggesting potential chemopreventive benefits.

Hormonal interactions, especially involving DHT and estrogen, play a key role in BPH development and treatment.

This review discusses 5-alpha reductase inhibitors, highlighting their long-term efficacy and tolerability in treating benign prostate hyperplasia, while also noting sexual dysfunction as a common adverse effect.

This study found that male 5αR1 knockout mice and obese Zucker rats treated with finasteride showed increased insulin resistance and hepatic steatosis, potentially implicating 5α-reductase activity in metabolic liver disease development.

This research discusses the potential antitumor effects of metformin, a common diabetes medication, noting its controversial influence on different malignant tumors and its uncertain mechanisms. Understanding these effects on tumors may aid in the development of new cancer treatments.

This research highlights the shift from surgical to pharmacologic and less invasive treatments for benign prostatic hyperplasia, noting finasteride's effectiveness in men with enlarged prostates and its ability to reduce acute urinary retention risk compared to alpha-blockers.

This article discusses the evolving field of hair transplantation surgery and reports no new experimental results, highlighting ongoing developments aimed at improving procedural success and doctor efficacy.

This review of Cynoglossum amabile, a traditional Chinese and ethnomedicine, provides insights into its uses, chemical components, biological activities, and toxicity. Highlighting its market potential, the study underscores the importance of indigenous knowledge in drug development despite noted hepatotoxic risk linked to its pyrrolizidine alkaloids.

This review discusses the historical and current use of androgen manipulation for treating benign prostatic hyperplasia and reports no new clinical results.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.

This thesis reviews the molecular mechanisms of androgen receptor functions, including receptor structure and interaction with other proteins, and reports no new experimental findings.

This study identified that methylation of the 5-AR2 gene promoter is linked to reduced expression of 5-AR2 protein, which may explain why some BPH patients are resistant to finasteride treatment.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.